Palobiofarma signs licensing agreement to develop novel adenosine-based immuno-oncology treatments

by Inveready Asset Management

Palobiofarma will receive an upfront payment of $15 million USD and is eligible to receive near-term clinical milestones and is eligible to receive development and commercial milestones on successful ...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Indexa Capital Group aumenta sus ingreso...

by Indexa Capital

Indexa Capital Group, sociedad matriz de Indexa Capital AV, Bewater As...

Photos Stream